BASF Agricultural Solutions has commissioned a new high double-digit million-euro fermentation facility at its Ludwigshafen site in Germany, signalling a decisive step in scaling up biological and biotechnology-based crop protection.
The so-called BioHub will produce biological fungicides, seed treatments and key intermediates using microbial fermentation – supporting BASF’s push to strengthen its BioSolutions™ portfolio as demand rises for more sustainable crop inputs.
The move comes as the agrochemical industry faces mounting regulatory pressure, shifting farmer and consumer expectations, and heightened scrutiny of conventional chemistries.
A key driver behind the investment is supply chain resilience.
Reducing reliance on external manufacturing
Until now, BASF relied on third-party contract manufacturers for commercial-scale production of its biological actives. Bringing fermentation in-house allows the company to reduce dependency on external partners and improve control over production.
“Own production capacities are a key element of our resilience, reducing reliance on third parties and giving us full control over our processes,” a BASF spokesperson told AgTechNavigator.
This shift enables more responsive planning and risk management, particularly in an environment of geopolitical instability and raw material constraints – issues highlighted in BASF’s recent financial results.
Flexibility to respond to volatile markets
Beyond resilience, the BioHub is designed to deliver manufacturing flexibility.
As a modular, scalable platform, the facility allows BASF to adjust production more quickly in response to changes in demand, supply disruptions or evolving market requirements. This is particularly important in the biologicals segment, where product pipelines are still rapidly evolving.
The ability to scale up or adapt production internally is expected to shorten response times and help stabilise supply for customers.
Linking research directly to industrial production
The BioHub also represents a strategic effort to more tightly integrate R&D with industrial-scale manufacturing.
“By bringing fermentation production in-house, we directly link our expertise in research with industrial-scale manufacturing,” said Dr Melanie Bausen-Wiens, BASF Agricultural Solutions board member responsible for technology.
This integration is expected to accelerate the development and commercialisation of new biological actives, reducing the time from lab discovery to market launch – a key competitive advantage in a fast-moving segment.
Initial production has already begun for actives such as Bacillus amyloliquefaciens (used in the biological fungicide Serifel®) and a precursor for Inscalis®, a novel insecticide.
First commercial batches from the facility are expected to be available to customers during 2026.
Lower energy intensity and site synergies
The Ludwigshafen site provides additional benefits through process efficiency and infrastructure synergies.
Fermentation processes used in biological production can be less energy intensive than traditional chemical synthesis, particularly when using renewable feedstocks such as glucose. At the same time, the site’s integrated infrastructure enables shorter process transitions, efficient resource use and economies of scale.
BASF highlighted the advantage of co-locating production units, which allows for streamlined operations and greater efficiency across the value chain.
Biologicals gain momentum amid industry pressure
The BioHub investment reflects broader structural changes in crop protection.
BASF noted that demand for biological solutions is being driven by the need to reduce agriculture’s environmental footprint, alongside advances in R&D and production technologies.
At the same time, the company faces ongoing litigation and regulatory challenges linked to conventional crop protection products, reinforcing the need to diversify its portfolio.
“We believe a good balance of using both conventional and biological technologies will help farmers produce enough healthy food while addressing societal expectations,” the spokesperson said.
Positioning for long-term growth
For BASF, scaling biological production is not about replacing chemistry entirely, but about building a more balanced, resilient and future-proof portfolio.
The BioHub gives the company the tools to reduce supply chain vulnerability; improve manufacturing agility; accelerate innovation cycles; and support sustainability-driven demand.
As the crop protection sector evolves, the facility positions BASF to compete more effectively in a market where biologicals are expected to play an increasingly important role alongside conventional solutions.
